Results from the global, phase 3 RATIONALE 302 clinical trial showed that TEVIMBRA prolonged the survival of patients who had received prior systemic treatment compared to chemotherapy
The authorization represents the first indication in the United States for TEVIMBRA
BASEL, Switzerland, BEIJING and CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the The US Food and Drug Administration (FDA) has authorized TEVIMBRA® (tislelizumab-jsgr) as monotherapy for adult patients with esophageal squamous cell carcinoma that is metastatic or cannot be resected following systemic chemotherapy that did not include a PD-(L)1 inhibitor.
The original text of this announcement, written in the source language, is the official version that is authentic. Translations are offered solely for the reader’s convenience and must refer to the original language text, which is the only legally valid one.
Contacts
Investor contact
Liza Heapes
+1 857-302-5663
Media contact
Kyle Blankenship
+1 667-351-5176